生物制药公司中国抗体制药向港交所递表
格隆汇获悉,7月8日,生物制药公司中国抗体制药有限公司(以下简称”中国抗体制药”或”公司”)向港交所递交上市申请资料,显示联席保荐人为中金公司和东方证券国际。
中国抗体制药是专门研究、发展、制造及商业化自身免疫性疾病疗法的香港生物制药公司,主要研制以单克隆抗体为基础的生物药。凭藉在香港的研发能力及在中国的制造能力,公司致力成为开发创新药以填补未满足医疗需求的全球领先生物制药公司。
公司在研产品享有乐观的市场前景。根据弗若斯特沙利文的资料,自身免疫性疾病(包括类风湿关节炎、系统性红斑狼疮干燥综合症及天疱疮)的全球市场规模于2018年达到1137亿美元,并预期将于2030年达到1913亿美元。由于缺乏有效的治疗方案,中国自身免疫性疾病的市场格局与全球市场截然不同。
于2018年,中国自身免疫性疾病市场规模达到人民币134亿元。鉴于诊断率上升加上未满足医疗的需求庞大,中国自身免疫性疾病市场预期将达到人民币1330亿元。
公司研发团队拥有从药物研发至IND阶段的全方位能力。公司的内部团队通过靶点确认、转化研究、功能检测、抗体人源化、安全性及有效性检测等主要活动推进临床前研究。截至最后实际可行日期,公司在香港拥有一支由26名上游研发人员组成的团队。于二零一七年、二零一八年及截至二零一九年四月三日止四个月,公司的研发成本分别为3260万元、4730万元及2020万元。
截至2017至2018年度,公司实现营收分别为341.1万元及866.6万元;实现净亏损分别为5190.1万元及8361万元。

募集资金用途:将分配至研发及商业化公司候选药物;将用于建设苏州生产基地,其主要用作核心产品SM03的商业化规模生产;将用于营运资金、扩大内部能力及其他一般企业用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.